Phase 3 studies comparing brodalumab with ustekinumab in psoriasis
N Engl J Med 2015;373:1318–28. doi: 10.1056/NEJMoa1503824
Brodalumab treatment resulted in a rapid reduction in the signs and symptoms of PsO. The median time to a PASI 75 response with 210 mg of brodalumab Q2W was 4 weeks, approximately twice as fast as the median time to a response with ustekinumab.
Early clinical studies suggested that brodalumab has efficacy in the treatment of PsO. Following on from this research, these results suggest that IL-17 receptor A plays a central role in PsO by directly driving downstream signalling in keratinocytes and inducing expression of proinflammatory molecules.
Keywords:
